Drugs / ARO-SOD1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05949294 | Jan 2024 → Mar 2025 | amyotrophic lateral sclerosis | Arrowhead Pharmaceuticals | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-06-27 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1 arrowheadpharma.com ↗
An application was submitted to an ethics committee in compliance with the Clinical Trial Notification process of the Australian Department of Health and Ageing, Therapeutic Goods Administration. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-06-27 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1 arrowheadpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARO-SOD1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05949294 ↗ |
| Route | Intrathecal | “single doses of ARO-SOD1 Injection by IT infusion” NCT05949294 ↗ |